Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 4/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433287 | 0.81 | HDAC9 (0.50) | HDAC9HCAR2KDM1ATDP1 | |
| SCHEMBL7434294 | 0.80 | SMN1; SMN2 (0.48) | HDAC9LMNA | |
| Trimethylammonium SCHEMBL27680853 | 0.79 | HDAC9 (0.45) | HDAC9HCAR2KDM1ALMNATDP1 | |
| Biphenyl SCHEMBL27506403 | 0.77 | HDAC9 (0.46) | HDAC9HCAR2KDM1ATDP1 | |
| SCHEMBL5835084 | 0.74 | GHSR (0.41) | KDM1AGHSR | |
| SCHEMBL9735969 | 0.74 | HDAC9 (0.44) | HDAC9HCAR2KDM1APIN1LMNA | |
| SCHEMBL5211064 | 0.74 | MAPK1 (0.36) | HDAC9KDM1ALMNATDP1NR1I3 | |
| SCHEMBL306307 | 0.74 | GHSR (0.43) | HDAC9HCAR2KDM1ANR1I3GHSR | |
| SCHEMBL4837190 | 0.74 | GHSR (0.43) | HDAC9HCAR2KDM1ANR1I3GHSR | |
| SCHEMBL18614341 | 0.74 | GHSR (0.43) | HDAC9HCAR2KDM1ANR1I3GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558253-A4 | PIPERIDINYL-ALPHA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20050250814-A1 | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2005-11-10 | — | — | US | disclosed |
| EP-1558253-A2 | PIPERIDINYL-ALPHA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004042351-A2 | PIPERIDINYL-ALPHA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250814-A1 | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity | CCR2, CCR1, CCRL2 | HDAC9 1105/4885HCAR2 59/4885KDM1A 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.